

Information for Health Care Professionals

Notice – Tiered Biologics Reimbursement Policy
Effective August 15, 2018
Updated January 31, 2025

- Effective August 15, 2018, Manitoba Health implemented a Tiered Biologics Reimbursement Policy.
- Tier 1 biologic products have been determined to be the most cost-effective agents which allow Pharmacare to achieve greater value for its publicly funded drug programs, treat a greater number of patients without increasing expenditures, and retain prescriber/patient choice.
- This Policy will ONLY apply to New Patients (biologic-naïve) and Existing Patients that have previously been trialed and deemed unresponsive to biologic therapy as follows:
 - New Patients (biologic-naïve):
 - Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
 - Existing Patients (ONLY those that have previously been trialed and deemed unresponsive to biologic therapy):
 - Currently on Tier 1 product → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
 - Currently on Tier 2 product → Fail → Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
- Refer to the Tiered Biologics Reimbursement Policy by Specialty section of this Notice for the products and indication(s) currently included in this policy.
- Prescribing Criteria for all products (including pediatrics if applicable) can be found here: <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>

Special Requests (Case-By-Case)


- To request special consideration for coverage on a case-by-case basis outside of this Policy, the clinician may write to the Provincial Drug Programs Review Committee (PDPRC), based upon the unique circumstances of the patient and alternative treatments tried.
- Additional information on the Provincial Drug Programs Review Process and requirements can be found at: <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>.

Tiered Biologics Reimbursement Policy Flowsheet

New Patients (Biologic-Naïve):



Existing Patients:



*If applicable, should additional Tier 2 products be specified under the Tiered Biologics Reimbursement Policy.

Tiered Biologics Reimbursement Policy by Specialty

Prescribing Criteria for all products (including pediatrics if applicable) can be found here: [Exception Drug Status \(EDS\) \(gov.mb.ca\)](https://gov.mb.ca/exception-drug-status)

Rheumatology (Rheumatoid Arthritis)

Tier 1	
Abrilada	(adalimumab)
Actemra	(tocilizumab)
Amgevita	(adalimumab)
Avsola	(infliximab)
Brenzys	(etanercept)
Cimzia	(certolizumab pegol)
Erelzi	(etanercept)
Hadlima	(adalimumab)
Hulio	(adalimumab)
Hyrimoz	(adalimumab)
Idacio	(adalimumab)
Inflectra	(infliximab)
Kevzara	(sarilumab)
Olumiant	(baricitinib)
Orencia	(abatacept)
Renflexis	(infliximab)
Rinvoq	(upadacitinib)
Riximyo	(rituximab)
Ruxience	(rituximab)
Rymti	(etanercept)
Simlandi	(adalimumab)
Simponi	(golimumab)
Simponi IV	(golimumab)
Truxima	(rituximab)
Xeljanz	(tofacitinib)
Xeljanz XR	(tofacitinib)
Yuflyma	(adalimumab)

Tier 2	
Kineret	(anakinra)